What we aim for


Fundamental research in the neuroscience field with new technologies in genetics and transcriptomics together with far reaching gene function research has led to the discovery of mechanistic details that is unprecedented.

The founders of Macrobian-Biotech are at the heart of such endeavors and that has lead to the identification of specific molecular pathways that regulate dopamine production specifically in midbrain dopamine neurons. Dysfunction of these neurons are at the center of neuro-psychiatric and neurological disorders such as Schizophrenia and Parkinson‘s. It is the ambition of Macrobian-Biotech to be at the forefront of clinical trial ready compound development vivifying novel treatments of neurological and neuropsychiatric diseases.